 |
Trials |
A phase I, multi-center, open-label, drug-drug interaction study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on dovitinib (TKI258) pharmacokinetics in patients with advanced solid tumorsCancer type: Solide tumores Phase: I Principal Investigator: Lassen Ulrik Country: DK Keywords: Denmark, Rigshospitalet, dovitinib, TKI-258, DDI Status: Inclusion completed Link to Clinicaltrials.gov: http://clinicaltrials.gov/ct2/show/NCT01700270?term=NCT01700270&rank=1 |